Patents by Inventor Christopher M. Moxham

Christopher M. Moxham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment
    Patent number: 9375488
    Abstract: The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 28, 2016
    Assignees: ImClone, LLC, ImmunoGen, Inc.
    Inventors: Paul J. Balderes, Scott W. Eastman, Hans K. Erickson, Dale L. Ludwig, Christopher M. Moxham, Gregory D. Plowman, Alan C. Rigby
  • COMPOUNDS TO FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR3) AND METHODS OF TREATMENT
    Publication number: 20150165067
    Abstract: The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.
    Type: Application
    Filed: December 11, 2014
    Publication date: June 18, 2015
    Applicants: IMCLONE LLC, IMMUNOGEN, INC.
    Inventors: Paul J. BALDERES, Scott W. EASTMAN, Hans K. ERICKSON, Dale L. LUDWIG, Christopher M. MOXHAM, Gregory D. PLOWMAN, Alan C. RIGBY
  • Antisense DNA constructs for expression of hybrid mRNAs driven by inducible, tissue-specific promoters
    Patent number: 6133245
    Abstract: A gene is regulated by introducing into a cell an inducible, tissue-specific antisense DNA construct. The antisense DNA construct comprises any inducible, tissue-specific gene, into which a DNA sequence antisense to any DNA sequence of the gene targeted for regulation has been inserted. The inducible, tissue-specific antisense DNA construct transcribes a hybrid messenger RNA containing an RNA sequence antisense to a sequence of the messenger RNA of the gene targeted for regulation. The hybrid messenger RNA also contains the RNA sequence of the inducible, tissue-specific gene. Some examples of suitable inducible genes include those selected from the group consisting of mammalian cytosolic phosphoenolpyruvate carboxykinase (PEPCK) (GTP, EC 4.1.1.32), mammalian atrial natriuretic factor (ANF), and mammalian alpha myosin heavy chain (.alpha.-MHC). In a preferred embodiment, the inducible, tissue-specific gene is the rat PEPCK gene.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: October 17, 2000
    Assignee: The Research Foundation of State University of New York
    Inventors: Craig C. Malbon, Christopher M. Moxham
  • Antisense DNA constructs for expression of hybrid MRNAs driven by inducible, tissue-specific promoters
    Patent number: 5858774
    Abstract: A gene is regulated by introducing into a cell an inducible, tissue-specific antisense DNA construct. The antisense DNA construct comprises any inducible, tissue-specific gene, into which a DNA sequence antisense to any DNA sequence of the gene targeted for regulation has been inserted. The inducible, tissue-specific antisense DNA construct transcribes a hybrid messenger RNA containing an RNA sequence antisense to a sequence of the messenger RNA of the gene targeted for regulation. The hybrid messenger RNA also contains the RNA sequence of the inducible, tissue-specific gene. Some examples of suitable inducible genes include those selected from the group consisting of mammalian cytosolic phosphoenolpyruvate carboxykinase (PEPCK) (GTP, EC 4.1.1.32), mammalian atrial natriuretic factor (ANF), and mammalian alpha myosin heavy chain (.alpha.-MHC). In a preferred embodiment, the inducible, tissue-specific gene is the rat PEPCK gene.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: January 12, 1999
    Assignee: The Research Foundation of State University of New York
    Inventors: Craig C. Malbon, Christopher M. Moxham